A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Biological therapies have transformed the management of psoriasis but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. To identify the immune determinants of response to the anti-TNF drug adalimumab and evaluate their predictive value, we performed in-depth immunomonitoring of blood immune cells of 67 psoriasis patients, before and during therapy. We assessed proximal TNF signaling events, by measuring NF-κB nuclear translocation anddoi:10.1101/2020.11.09.20228502 fatcat:amhyptgwjfbsxhn6hb6zvd2lc4